Articles

Digital Insights: No Digital Marketing Guidance? We Don’t Care.

Big pharma digital marketing campaigns are plowing full steam ahead, helping both consumers and patients, even without any clear guidance from FDA.
Post Date: 03/28/2012
Author: Michele V. Wagner, Senior Digital Editor

PharmaView: Time Away from a Life in Big Pharma

“It is worth having dreams,” and worth fulfilling them, says former Novartis employee Anna Kroczak.
Post Date: 03/15/2012
Author: Paul Thomas, Senior Editor

Think You Can Teach? Tips on Moving from Pharma to Academia

You will need to work at least twice as hard, says an ex-Pfizer scientist. "This is NOT a retirement, fade-into-the-sunset kind of job."
Post Date: 03/15/2012
Author: Michael Pollastri

Jobs and Salaries: Pharma's Professionals Piece Together the Future

Our eighth annual Job Satisfaction and Salary Survey says the big picture is brighter, though not clearer.
Post Date: 03/07/2012
Author: Paul Thomas, Senior Editor

Pharma Workers Enter the Era of Free Agency

Tectonic shifts are changing the way pharma workers will view loyalty and employment, says Kelly Services’ Alan Edwards.
Post Date: 03/06/2012
Author: Paul Thomas, Senior Editor

Derek Lowe: Where Are Pharma’s Jobs Going?

Insights on the 2012 job market from an industry insider.
Post Date: 03/02/2012
Author: Paul Thomas, Senior Editor

John Challenger: Cross-Currents Buffeting Pharma Make Predicting 2012 Job Market Difficult

We have a ways to go before any kind of equilibrium is established in the pharma workforce, the job market guru says.
Post Date: 02/13/2012
Author: Paul Thomas, Senior Editor

Digital Insights: Scientists & Twitter

Twitter's impact on the scientific community and scientific literature citations in particular is growing at a rapid rate.
Post Date: 02/06/2012
Author: Michele V. Wagner, Senior Digital Editor

PharmaView: Coming to America: European Companies Buy In and Lease

"OUS" companies are enjoying the U.S. market, and creating a few jobs along the way.
Post Date: 02/06/2012
Author: Paul Thomas, Senior Editor

PharmaView: Can Manufacturing Be Sexy for Millennials?

If not, maybe greed can help overcome manufacturing’s PR problem with young professionals.
Post Date: 02/03/2012
Author: Paul Thomas, Senior Editor

From the Editor: A Culture of Arrogance

Analysts say that 2012 may prove to be pharma’s most challenging year ever.
Post Date: 02/03/2012
Author: Agnes Shanley, Editor in Chief

Digital Insights: Novartis Overtakes Pfizer in 2011 Good Web Buzz Rankings

Zeta Interactive has published its annual end-of-year Buzz Report, recapping the most buzzworthy pharmaceutical brands’ trends and stories from 2011.
Post Date: 01/18/2012
Author: Michele V. Wagner, Senior Digital Editor

Groundbreakers: Tomorrow's Drug Manufacturing Facilities

Modular construction and disposable process equipment are maximizing agility and minimizing risk
Post Date: 01/11/2012
Author: Agnes Shanley, Editor in Chief, and Paul Thomas, Senior Editor

Pharma Facilities: Modular Gains Momentum

While modular drug facilities have had inconsistent results to date, they are an inevitable part of pharma’s future. We speak with modular construction expert Pär Almhem.
Post Date: 12/15/2011
Author: Paul Thomas, Senior Editor

Funny Pharm: You Write the Caption & Win: December 2011

"Funny Pharm," features drawings by award-winning cartoonist Jerry King. Submit your caption and win
Post Date: 12/14/2011
Author:

PharmaView: Fake Drugs: Why Business is Booming

It’s time to make counterfeiting less economically tantalizing.
Post Date: 12/14/2011
Author: Paul Thomas, Senior Editor

Digital Insights: Pharma's Digital Revolution. Better Late Than Never

Big Pharma’s concentration on digital marketing nearly tripled in 2011 with consumers increasing reliance on technical gadgets and social media.
Post Date: 12/14/2011
Author: Michele V. Wagner, Senior Digital Editor

Making the Case for Personalized Medicine

The personalized medicine era is here, though technical, legal, regulatory and payor issues are still barriers.
Post Date: 12/05/2011
Author: Antoinette F. Konski, Partner, Foley and Lardner LLP

From the Editor: Adulteration, 21st Century Style

As legislators and the courts re-examine an old fashioned word, sins of omission will count as much, if not more, than sins of commission.
Post Date: 11/30/2011
Author: Agnes Shanley, Editor in Chief

FDA: Seven Areas for Growth and Improvement

While ambitious, the FDA's new report on biomedical innovation indicates that it is listening to industry and working to harness the power and potential of today's technologies.
Post Date: 10/28/2011
Author: Antoinette F. Konski, Partner, Foley and Lardner LLP